Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII).

about

The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs

P2860

Q58718992-2A8B85E7-15B4-4B12-8201-4C890384D5A8

P2860

Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII).

Item

http://www.wikidata.org/entity/Q46718088

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Approving cancer treatments ba ...... Innovation Indicators™ (CII).

@en

Approving cancer treatments ba ...... tinuous Innovation Indicators™

@nl

type

Item

label

Approving cancer treatments ba ...... Innovation Indicators™ (CII).

@en

Approving cancer treatments ba ...... tinuous Innovation Indicators™

@nl

prefLabel

Approving cancer treatments ba ...... Innovation Indicators™ (CII).

@en

Approving cancer treatments ba ...... tinuous Innovation Indicators™

@nl

P1476

Approving cancer treatments ba ...... Innovation Indicators™ (CII).

@en

P2093

David Grainger

http://www.w3.org/2001/XMLSchema#string

Jacqueline Zummo

http://www.w3.org/2001/XMLSchema#string

Mario Campone

http://www.w3.org/2001/XMLSchema#string

Neon Brooks

http://www.w3.org/2001/XMLSchema#string

Rose Li

http://www.w3.org/2001/XMLSchema#string

Samuel Thomas

http://www.w3.org/2001/XMLSchema#string

Scott Shortenhaus

http://www.w3.org/2001/XMLSchema#string

Silvia Paddock

http://www.w3.org/2001/XMLSchema#string

P2860

A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474

On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

ALK and NSCLC: Targeted therapy with ALK inhibitors

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Detecting an overall survival benefit that is derived from progression-free survival

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.

Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.

P304

212507

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7573/DIC.212507

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29167693

http://www.w3.org/2001/XMLSchema#string

P932

5699106

http://www.w3.org/2001/XMLSchema#string

Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII).

about

P2860

P2860

Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932